|
Blue Spring Corporation is the pioneer (1982) in commercialization of double-pass reverse osmosis technology, for the production of Water-for-Injection1 per United States Pharmacopoeia. These pharmaceutical USP water systems, based on double-pass reverse osmosis technology are simple, compact, economical and reliable, compared with conventional distillation and deionization based pharmaceutical USP water systems. At the present time, Blue Spring offers three different series of pharmaceutical USP water systems to meet your USP water requirements: · WFI-EDI Series Combination double pass reverse osmosis electrodeionization water purification systems. These latest pharmaceutical USP water purification systems use a unique combination of double pass reverse osmosis and electrodeionization (EDI) technologies to produce Water-for-Injection1 according to USP 23-29. They also produce Purified Water1 according to USP 23-29 and can be used in manufacturing product lines that require both Water-for-Injection and Purified Water. Output capacities are available from 750 LPH up to 5,000 LPH. · WP-EDI Series Combination single pass reverse osmosis electrodeionization water purification systems. These latest pharmaceutical USP water purification systems use a unique combination of single pass reverse osmosis and electrodeionization (EDI) technologies, to produce Purified Water1 according to USP 23-29. Output capacities are available from 850 LPH up to 6,000 LPH. Smaller systems are available in WP-DI series with capacities from 90 LPH up to 230 LPH. These smaller systems use combination of reverse osmosis and conventional ion-exchange deionization technologies. · WFI Series Double Pass Reverse Osmosis Water Purification Systems. These pharmaceutical water purification systems produce both Water for Injection1 and Purified Water categories according to USP 22 or earlier. Output capacities are available from 130 LPH up to 1,350 LPH. For multiple points of use covering the entire manufacturing establishment, Blue Spring offers a novel, closed-loop output configuration, for both WFI-EDI and WP-EDI Series pharmaceutical USP water systems. The closed-loop output configuration eliminates storage tanks, re-circulation pumps, sub-micron filters, water heaters and coolers, and other external equipment, used in the conventional process water distribution network that can re-contaminate the pharmaceutical USP process water. In the closed loop output system, constant recirculation of the pharmaceutical process water, through the RO membranes, continuously enhances both chemical and microbiological quality of the water. The closed-loop feature is designated as Option "R".
With over 27 years of experience in pharmaceutical water systems, when you go with Blue Spring, you are in safe hands!
For sales and applications assistance, please click here
To learn more about closed loop output configuration, please click here
To learn more about USP standards for water, please click here
1 According to U.S. FDA, USP purified water and USP WFI are components or “ingredient materials” as they are termed by the USP, intended to be used in the production of drug products. Neither FDA nor USP considers them as drug products. These two water categories are popularly used within pharmaceutical and medical device manufacturing establishments. |
|
PHARMACEUTICAL USP WATER SYSTEMS, PHARMACEUTICAL USP WATER FOR INJECTION SYSTEMS, PHARMACEUTICAL USP PURIFIED WATER SYSTEMS |
|
Blue Spring has the most diversified line of |
|
|
|||||